Investigation of sensory neurogenic components in a bleomycin-induced scleroderma model using transient receptor potential vanilloid 1 receptor- and calcitonin gene-related peptide-knockout mice

Arthritis and Rheumatism

Volumn 58, Issue 1, 2008, Pages 292-301

  Szabó, Árpád ^a   Czirják, László ^a   Sándor, Zoltán ^a   Helyes, Zsuzsanna ^a   Lászlo, Terézia ^a   Elekes, Krisztián ^a   Czömpöly, Tamás ^a   Starr, Anna ^b   Brain, Susan ^b   Szolcsányi, János ^a   Pintér, Erika ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; AMINO ACID; BLEOMYCIN; CALCITONIN GENE RELATED PEPTIDE; CAPSAICIN; COLLAGEN; HYDROXYPROLINE; NEUROPEPTIDE; PHOSPHATE BUFFERED SALINE; VANILLOID RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNOMODULATION; INFLAMMATION; KNOCKOUT MOUSE; MOUSE; NERVE ENDING; NOCICEPTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SCLERODERMA; SENSORY NERVE; SKIN FIBROSIS; SKINFOLD;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLEOMYCIN; CALCITONIN GENE-RELATED PEPTIDE; COLLAGEN TYPE I; DERMIS; DISEASE MODELS, ANIMAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEURONS, AFFERENT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SCLERODERMA, SYSTEMIC; TRPV CATION CHANNELS;

EID: 38149079837     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23168     Document Type: Article

References (50)

1. Abraham DJ, Varga J. Scleroderma: from cell and molecular mechanisms to disease models [review]. Trends Immunol 2005;26:587-95.
2. Denton CP, Black CM, Abraham DJ. Mechanisms and consequences of fibrosis in systemic sclerosis [review]. Nat Clin Pract Rheumatol 2006;2:134-44.
3. Trojanowska M. Molecular aspects of scleroderma. Front Biosci 2002;7:608-18.
4. Sappino AP, Masouye I, Saurat JH, Gabbiani G. Smooth muscle differentiation in scleroderma fibroblastic cells. Am J Pathol 1990;137:585-91.
5. Sakkas LI. New developments in the pathogenesis of systemic sclerosis [review]. Autoimmunity 2005;38:113-6.
6. Jimenez SA, Christner PJ. Murine animal models of systemic sclerosis [review]. Curr Opin Rheumatol 2002;14:671-80.
7. Yamamoto T, Takagawa S, Katayama I. Animal model of sclerotic skin. I. Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999;112:456-62.
8. Umezawa H, Maeda K, Takeuchi T, Okami Y. New antibiotics, bleomycin A and B. J Antibiot (Tokyo) 1966;19:200-9.
9. Grollman AP, Takeshita M, Pillai KM, Johnson F. Origin and cytotoxic properties of base propenals derived from DNA. Cancer Res 1985;45:1127-31.
10. Twentyman PR. Bleomycin: mode of action with particular reference to the cell cycle. Pharmacol Ther 1983;23:417-41.
11. Sebti SM, Jani JP, Mistry JS, Gorelic E, Lazo JS. Metabolic inactivation: a mechanism of human tumor resistance to bleomycin. Cancer Res 1991;51:227-32.
12. Adamson IV, Bowden DH. The pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Pathol 1974;77:185-98.
13. Finch WR, Rodnan GP, Buckingham RB, Prince RK, Winkelstein A. Bleomycin-induced scleroderma. J Rheumatol 1980;7:651-9.
14. Szolcsanyi J. Capsaicin-sensitive sensory nerve terminals with local and systemic efferent functions: facts and scopes of an unorthodox neuroregulatory mechanism. Prog Brain Res 1996;113:343-9.
15. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997;389:816-24.
16. Hwang SW, Cho H, Kwak J, Lee SY, Kang CJ, Jung J, et al. Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc Natl Acad Sci U S A 2000;97:6155-60.
17. Barnes PJ. Asthma as an axon reflex. Lancet 1986;1:242-5.
18. Ferrel WR, Lam FY. Sensory neuropeptides in arthritis. In: Geppetti P, Holzer P, editors. Neurogenic inflammation. Boca Raton (FL): CRC Press; 1996. p. 211-27.
19. Helyes Z, Szabo A, Nemeth J, Jakab B, Pinter E, Banvolgyi A, et al. Antiinflammatory and analgesic effects of somatostatin released from capsaicin-sensitive sensory nerve terminals in a Freund's adjuvant-induced chronic arthritis model in the rat. Arthritis Rheum 2004;50:1677-85.
20. Keeble J, Russell F, Curtis B, Starr A, Pinter E, Brain SD. Involvement of transient receptor potential vanilloid 1 in the vascular and hyperalgesic components of joint inflammation. Arthritis Rheum 2005;52:3248-56.
21. Naukkarinen A, Jarvikallio A, Lakkaporpi J, Harvima IT, Harvima RJ, Horsmanheimo M. Quantitative histochemical analysis of mast cells and sensory nerves in psoriatic skin. J Pathol 1996;180:200-5.
22. Gutwald J, Goebeler M, Sorg CJ. Neuropeptides enhance irritant and allergic contact dermatitis. J Invest Dermatol 1991;96:695-8.
23. Buzzi MG, Moskowitz MA. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 1990;99:202-6.
24. Tominaga M, Tominaga T. Structure and function of TRPV1. Pflugers Arch 2005;451:143-50.
25. Bunker CB, Terenghi G, Springall DR, Polak JM, Dowd PM. Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon. Lancet 1990;336:1530-3.
26. Terenghi G, Bunker CB, Liu YF, Springall DR, Cowen T, Dowd PM, et al. Image analysis quantification of peptide-immunoreactive nerves in the skin of patients with Raynaud's phenomenon and systemic sclerosis. J Pathol 1991;164:245-52.
27. Bunker CB, Goldsmith PC, Leslie TA, Hayes N, Foreman JC, Dowd PM. Calcitonin gene-related peptide, endothelin-1, the cutaneous microvasculature and Raynaud's phenomenon. Br J Dermatol 1996;134:399-406.
28. Brain SD, Williams TJ, Tippins JR, Morris HJ, MacIntyre I. Calcitonin gene-related peptide is a potent vasodilator. Nature 1985;313:54-6.
29. Davis JB, Gray J, Gunthorpe MJ, Hatcher JP, Davey PT, Overend P, et al. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 2000;405:183-7.
30. Salmon AM, Damaj I, Sekine S, Picciotto MR, Marubio L, Changeux JP. Modulation of morphine analgesia in αCGRP mutant mice. Neuroreport 1999;10:849-54.
31. Yamamoto T, Takagawa S, Katayama I, Mizushima Y, Nishioka K. Effect of superoxide dismutase on bleomycin-induced dermal sclerosis: implications for the treatment of systemic sclerosis. J Invest Dermatol 1999;113:843-7.
32. Distler JH, Jungel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007;56:311-22.
33. Woessener JF Jr. The determination of hydroxyproline in tissue and protein samples containing small proportions of this amino acid. Arch Biochem Biophys 1961;93:440-7.
34. Walker NJ. A technique whose time has come. Science 2002;296:557-9.
35. Radonic A, Thulke S, Mackay IM, Landt O, Siegert W, Nitsche A. Guideline to reference gene selection for quantitative real-time PCR. Biochem Biophys Res Commun 2004;313:856-62.
36. Bolcskei K, Helyes Z, Szabo A, Sandor K, Elekes K, Nemeth J, et al. Investigation of the role of TRPV1 receptors in acute and chronic nociceptive processes using gene-deficient mice. Pain 2005;117:368-76.
37. Szallasi A, Cruz F, Gepetti P. TRPV1: a therapeutic target for novel analgesic drugs? Trends Mol Med 2006;12:545-54.
38. Szabo A, Helyes Z, Sandor K, Bite A, Pinter E, Nemeth J, et al. Role of transient receptor potential vanilloid 1 receptors in adjuvant-induced chronic arthritis: in vivo study using gene-deficient mice. J Pharmacol Exp Ther 2005;314:111-9.
39. Banvolgyi A, Palinkas L, Berki T, Clark N, Grant AD, Helyes Z, et al. Evidence for a novel protective role of the vanilloid TRPV1 receptor in a cutaneous contact allergic dermatitis model. J Neuroimmunol 2005;169:86-96.
40. Massa F, Sibaev A, Marsicano G, Blaudzun H, Storr M, Lutz B. Vanilloid receptor (TRPV1)-deficient mice show increased susceptibility to dinitrobenzene sulfonic acid induced colitis. J Mol Med 2006;84:142-6.
41. Okajima K, Harada M. Regulation of inflammatory responses by sensory neurons: molecular mechanism(s) and possible therapeutic applications. Curr Med Chem 2006;13:2241-51.
42. Yamamoto T, Kuroda M, Nishoika K. Animal model of sclerotic skin. III. Histopathological comparison of bleomycin-induced scleroderma in various mice strains. Arch Dermatol Res 2000;292:535-41.
43. 2A receptors in diffuse dermal fibrosis: pathogenic role in human dermal fibroblasts and in a murine model of scleroderma. Arthritis Rheum 2006;54:2632-42.
44. Yamamoto T, Nisshioka K. Increased expression of p53 and p21 (Waf1/Cip1) in the lesional skin of bleomycin-induced scleroderma. Arch Dermatol Res 2005;296:509-13.
45. Matsushita M, Yamamoto T, Nishioka K. Plasminogen activator inhibitor-1 is elevated, but not essential, in the development of bleomycin-induced murine scleroderma. Clin Exp Immunol 2004;139:429-38.
46. Lembeck F, Holzer P. Substance P as neurogenic mediator of antidromic vasodilation and neurogenic plasma extravasation. Naunyn Schmiedebergs Arch Pharmacol 1979;310:175-83.
47. Pinter E, Helyes Z, Szolcsanyi J. Inhibitory effect of somatostatin on inflammation and nociception. Pharmacol Ther 2006;112:440-56.
48. Dalsgaard CJ, Jernbeck J, Stains W, Kjartansson J, Haegerstrand A, Hokfelt T, et al. Calcitonin gene-related peptide-like immunoreactivity in nerve fibers in the human skin: relation to fibers containing substance P-, somatostatin- and vasoactive intestinal polypeptide-like immunoreactivity. Histochemistry 1989;91:35-8.
49. Cooke JP, Marshall JM. Mechanisms of Raynaud's disease [review]. Vasc Med 2005;10:293-307.
50. Komocsi A, Tovari E, Kovacs J, Czirjak L. Physical injury as provoking factor in three patients with scleroderma. Clin Exp Rheumatol 2000;18:622-4.